Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 85

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 85
---
 payment for our products and exposure ...  
  an outbreak of a contagious disease, including COVID-19, which may cause us or our distributors, third party vendors and manufacturers and/or customers to temporarily suspend our or their respe...  
  natural disasters, political and economic instability, including wars, terrorism, and political unrest, boycotts, curtailment of trade, and other business restrictions;                              
  certain expenses including, among others, expenses for travel, translation and insurance; and                                                                                                         
  regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U. S. Foreign Corrupt Practices Act...  

Any of these factors could significantly harm our
future international expansion and operations and, consequently, our results of operations.

Certain of our directors and officers may have interests that
compete with ours.

Certain of our directors currently operate, manage
or are engaged as officers and/or directors of other entities, which may have similar or different objectives than ours. Such activities
could detract from the time these people have to allocate to our affairs. For example, Adi Zuloff-Shani, our Chief Executive Officer,
serves as Chief Technology Officer of SciSparc Ltd. (Nasdaq: SPRC), or SciSparc; Amitay Weiss, the Chairman of our Board of Directors,
serves as the Chairman of the Board of Directors of SciSparc; and Oz Adler, one of our directors, serves as the Chief Executive Officer
and Chief Financial Officer of SciSparc. Further to the agreement signed between us and SciSparc in March 2022, the purposes of which
is to explore the technological and business feasibility of creating pharmaceutical solutions for several indications including CNS related
indications by combining the respective capabilities and technologies of both parties. In June 2023, we announced that, as part of our
ongoing collaboration with SciSparc, we entered into a research agreement with the Hebrew University of Jerusalem to evaluate our and
SciSparc’s combination treatment for obesity and metabolic syndrome. Moreover, certain of our directors and officers are affiliated
with our current shareholders, and may have different interests than other shareholders. For additional information regarding related
party transactions and potential conflicts of interest, see “ Item 7. B. Related Party Transactions.” Under the Business Corporations
Act (British Columbia) [SBC 2002] c.57, or the BCBCA, each director